15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry data
R Baldassano(Herlev Hospital), Harland S. Winter(Massachusetts General Hospital), M Dubinsky, Johanna C. Escher(Erasmus MC - Sophia Children’s Hospital), J. M. Fell(Herlev Hospital), Jeffrey Hyams(Herlev Hospital), Gigi Veereman, Salvatore Cucchiara(Massachusetts General Hospital), Sibylle Koletzko(LMU Klinikum), Anne M. Griffiths(University of Toronto), Richard B. Colletti(Greenville College), James Markowitz(Philadelphia University), P. Callegari, B. D. Gold(Emory University), R Wright(University Hospital Complex Of Vigo), Mark R. Molenda, F. Ruemmele, Subra Kugathasan(Children's Healthcare of Atlanta), K. Linda Tang, William A. Faubion(Mayo Clinic in Arizona)
Cited by 3
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k